pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 14·1 min read
save

Novo Nordisk rebrands as "Novo" to signal renewed focus amid slipping market share

Sep 14, 2026·read at STAT ↗Negative

Novo Nordisk announced it will drop "Nordisk" from its name, adopting the shorter brand "Novo" along with a new slogan "Lasting Health Starts Now" as part of a cultural shift.

The company says the rebrand is intended to convey greater focus, speed and impact as it seeks to regain momentum in the competitive diabetes and obesity space.

Novo has seen its share price fall about 20% over the past year after losing ground to rivals such as Eli Lilly and delivering a weaker pipeline than expected.

Analysts view the move as a signal that the Danish firm is trying to reset its image and rally investor confidence, though the market reaction remains uncertain.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: What’s in a name? Novo looks to a rebrand”

read at STAT ↗
449 words · retrieved Sep 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO10Novo Nordisk Inc3ELI LILLY CO2LILLY2ASTRAZENECAEli Lilly and Co
drugs
Obesity4
topics
Obesity4Type 2 Diabetes2Breast CancerGLP-1 receptorOncology

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • Oct 9Hengrui has become the go-to source of China biopharma innovation. What’s its secret?Fierce Biotech
  • Oct 6The top biopharma conferences in 2027BioPharma Dive
  • Sep 23Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • Sep 22STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge programSTAT